A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate how the body processes and removes mirikizumab. The study
will also evaluate safety and disease response in pediatric participants with UC taking
mirikizumab. The study will last about 52 weeks and may include up to 17 visits.